Comparative Pharmacology
Head-to-head clinical analysis: MONISTAT 7 versus MYCOSTATIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MONISTAT 7 versus MYCOSTATIN.
MONISTAT 7 vs MYCOSTATIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Miconazole, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, reducing ergosterol synthesis and disrupting fungal cell membrane integrity.
Mycostatin (nystatin) is a polyene antifungal antibiotic that binds to ergosterol in the fungal cell membrane, forming pores that increase membrane permeability, leading to leakage of intracellular contents and cell death.
Intravaginal administration of 100 mg miconazole nitrate suppository once daily at bedtime for 7 days.
Nystatin suspension: 400,000-600,000 units (4-6 mL) orally four times daily for 7-14 days. Nystatin pastilles: 200,000-400,000 units (1-2 pastilles) orally four to five times daily for 7-14 days.
None Documented
None Documented
Terminal elimination half-life is approximately 24-30 hours following intravaginal administration; clinical significance: supports once-daily dosing.
Not applicable (nystatin is not absorbed systemically; no meaningful plasma half-life exists). For reference, if absorbed, the terminal half-life would be approximately 4-6 hours, but this is not clinically relevant.
Primarily via feces (approximately 87-93% of dose) as unchanged drug and metabolites; renal excretion negligible (<1%).
Nystatin is not absorbed from the gastrointestinal tract, skin, or mucous membranes. After oral administration, virtually all of the drug is excreted unchanged in feces. Renal excretion is negligible (<0.1%).
Category C
Category C
Antifungal
Antifungal